首页> 美国卫生研究院文献>The Oncologist >MicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer
【2h】

MicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer

机译:MicroRNA表达谱在乳头状甲状腺癌的管理中。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Papillary thyroid cancer (PTC) is the major contributor to the dramatically increasing incidence of thyroid cancer. Low-risk PTC shows the most rapid rate of increase because of changing trends in neck imaging and the use of fine needle aspiration to investigate thyroid nodules. The need for a paradigm shift in the management of these patients, to provide personalized treatment and surveillance plans, has led to the focus on molecular biomarker research. MicroRNAs (miRNAs) compose a class of molecules with promising applications for every stage of PTC management, including diagnosis, prognosis, treatment, and surveillance. Although most of the miRNA studies are currently preclinical, given the rapid progress of scientific discovery, clinical trials will not be far away. Thyroid clinicians will be expected to have good insights into the current status of PTC-related molecular translational research. This article focuses on the potential roles of miRNA in PTC management in the context of contemporary recommended clinical practice.
机译:甲状腺乳头状癌(PTC)是导致甲状腺癌发病率急剧上升的主要因素。低风险PTC显示出最快的增长速度,这是因为颈部影像学的变化趋势以及使用细针抽吸术检查甲状腺结节所致。为了提供个性化的治疗和监测计划,对这些患者进行管理的范式转变的需求导致了对分子生物标志物研究的关注。 MicroRNA(miRNA)构成了一类分子,在PTC管理的每个阶段都具有广阔的应用前景,包括诊断,预后,治疗和监视。尽管目前大多数miRNA研究都处于临床前阶段,但随着科学发现的迅速发展,临床试验将遥遥无期。甲状腺临床医生将有望对PTC相关分子翻译研究的现状有深入的了解。本文重点关注在当代推荐的临床实践中,miRNA在PTC管理中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号